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Abstract 
Gangliosides, glycosphingolipids that carry at least one sialic acid residue, are 
enriched in the plasma membranes of neurons. Despite their abundance, little is known 
about the molecules they interact with in the plasma membrane and how their metabolism 
differs from cell-to-cell.  Rare human disorders of ganglioside biosynthesis and 
catabolism have devastating neurological defects and currently have no treatments. My 
thesis project aims to take a two pronged approach to help understand ganglioside 
function and ganglioside metabolic disorders. The first aim was to identify novel 
ganglioside interacting proteins by utilizing an unbiased screening method, mass 
spectrometric interaction analyses (iTRAQ) mass spectrometry. Primary rat cerebellar 
granule neuron cell surface proteins were isolated and ganglioside specific interacting 
proteins were collected via affinity chromatography on GT1b- and GM1-derivatized 
beads. iTRAQ and subsequent validation studies revealed reproducible differences 
between GT1b- and GM1-bound proteins from biological replicates. Rigorous statistical 
analyses revealed six GT1b-selective binding proteins, three of which suggested that 
GT1b participates in the regulation of glutamate-receptor surface expression. The second 
aim was to develop methods to quantify ganglioside metabolism in single cells. 
Fluorescently labeled gangliosides and various precursor glycosphingolipids were added 
to primary neuronal cultures. Separation of metabolites and ultrasensitive quantification 
was achieved using capillary electrophoresis coupled to a laser-induced fluorescence 
detection system with a sub-zeptomole (10e-21 mole) detection limit. Addition of labeled 
glycosphingolipids to primary cerebellar cultures allowed determination of anabolic and 
catabolic products at the single cell level. Neuronal and glial cells could be differentiated 
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with this method and heterogeneity was distinguishable among cells when analyzed on 
the single cell level. Analysis of metabolism in culture homogenates (thousands of cells) 
was consistent with metabolism averaged from a large number of single cells. Through 
understanding both ganglioside metabolism and the molecules that gangliosides interact 
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Chapter 1: Introduction 
Section 1.1: Gangliosides Structure and Metabolism 
Glycans play roles in cell-cell interactions and signaling pathways (EGF, insulin), 
and defects in glycan expression  play important roles in disease states (cancer, 
metabolism) 1-4. Gangliosides are the dominant species of glycans on nerve cells in the 
mammalian brain with ~90% being GM1, GT1b, GD1a and GD1b 5. They are 
glycosphingolipids (GSLs) that carry at least one sialic acid residue, and it is the 
variations in glycans that give GSLs their unique properties (Figure 1.1).  
Figure  1.1 Ganglioside 
structure and metabolic 
pathway. GT1b structure 
is shown above the 





carry at least one sialic 
acid residue. The number 
and linkage of the sialic acid(s) to the core glycan structure results in unique molecules 
with distinct properties 1,6. 
Changes in ganglioside expression occur over development and they are highly 
spatiotemporally regulated. There is a shift from simple gangliosides in the developing 
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brain, such as GM3 and GD3, to the four major brain gangliosides GM1, GT1b, GD1a 
and GD1b. This increase in overall ganglioside expression, begins around the third 
trimester in humans 7,8. The change occurs due to shifts in glycosyltransferases spatial 
and temporal expression levels over development 9. The increase in ganglioside 
expression is also coincident with an increase in myelination 10.  
Gangliosides are located in the plasma membrane with their ceramide potion 
inserted into the outer leaflet of the bilayer and their glycan head is extended into the 
extracellular space, this topology is conserved through biosynthesis. Gangliosides are 
created stepwise with specific glycosyltransferases adding various glycans to the 
ceramide core. This synthesis begins in the endoplasmic reticulum and then is modified 
in the Golgi before the final ganglioside product is transported to the plasma membrane. 
When glycolipids are internalized from the plasma membrane they are broken down in a 
step wise manner once they reach the lysosome 11. The biosynthesis and degradation of 
gangliosides is a relatively rapid pathway, as evidenced by addition of a 
glycosphingolipid biosynthesis inhibitor (1R,2R)-1-phenyl-2-hexadecanoylamino-3-
pyrrolidino-1-propanol (P4) 12. Within 24 h the cell surface is cleared of gangliosides due 
to P4 addition. The catabolic and biosynthetic pathways of gangliosides are well 
established, but cell-to-cell variability in these pathways is not well known. 
 
Section 1.2: Ganglioside Interacting Proteins and the Glycosynapse 
Gangliosides are known to play roles in diverse signaling pathways involved in 
the immune system, insulin resistance, cancer, and development and stability of axons 1-3. 
They can interact both laterally (cis) within the same membrane and in trans with 
molecules on opposing cellular surfaces. This allows gangliosides to play a role in both 
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regulation and recognition pathways involved in cellular signaling and physiology 13. 
Gangliosides can cluster in the cell membrane, this is believed to be due to their cis 
interactions because they typically have long unsaturated lipid chains that associate 
laterally via hydrophobic interactions and their head group can act both as a hydrogen 
bond donor and acceptor due to the presence of their hydroxyl and acetamide group 14. It 
has been demonstrated by many scientific groups that gangliosides are found in lipid rafts 
with important signaling complexes 2,15,16.  This signaling platform is also referred to as 
the glycosynapse, a term coined by Dr. Sen-Itiroh Hakomori 15, where the glycan is not 
thought of as a passive marker for a signaling platform, but rather plays an active role in 
the signaling pathway. This term is analogous to the “immunological synapse” which 
controls adhesion and signaling between immunocytes 17.  
When the normal glycolipid biosynthesis pathways are disrupted so too is the 
glycosynapse. Mice with disrupted glycolipid glycosyltransferase genes demonstrate 
defects in normal lipid raft formation. When ganglioside biosynthesis is blocked, 
gangliosides accumulate behind this block and reach the same total amount of 
ganglioside as in wild type, albeit with a different composition of glycolipids. Other lipid 
concentrations and distributions are not affected in these knockouts (i.e. cholesterol, 
phospholipids etc.), but common lipid raft markers are altered in these mice. For 
example, in GM2/GD2 (B4galnt1-null) and GD3 synthase (St8gal1) single or double 
knockout mice, common lipid raft markers like flotillin-1 and caveolin-1 are dispersed 
from the lipid rafts, but the same total protein concentration is maintained. It is believed 
that the disorganization of these lipid raft signaling platforms may lead to age related 
neurodegeneration and improper complement activation 18. A better understanding of the 
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role of gangliosides in lipid rafts in both cis and trans relationships is crucial to piecing 
together important disease related signaling pathways.  
Section 1.3 Trans interactions - Myelin Associated Glycoprotein (MAG) Structure 
and Function 
One commonly studied ganglioside trans interaction is with MAG, which is a 
transmembrane glycoprotein that is found in the membranes of Schwann cells and 
oligodendrocytes 19. In the CNS is only found on the inner most myelin wrap on the 
membrane directly apposing the neuronal membrane, it is not present in compact myelin. 
MAG is a minor component of myelin, only making up about 1% of the total protein in 
CNS myelin and 0.1% in PNS myelin 20. Despite its low abundance, this protein plays a 
crucial role in cell-cell interactions which can stabilize the myelin-axon interface in 
healthy states, but it is a potent inhibitor of axonal regeneration in times of injury.  
MAG is a 100-kDa transmembrane glycoprotein containing five extracellular Ig-
like domains and is heavily glycosylated – about 30% of its weight is carbohydrate – this 
makes this glycoprotein very heterogeneous 21.  Myelin rich membrane fractions 
containing MAG  can be isolated utilizing centrifugation and gradients for neurite 
inhibition growth assays 12,22.  MAG is highly conserved over evolution, with human and 
rat MAG 89% homologous at the nucleotide level and 95% homologous at the amino 
acid sequence level 23  
In rodents, myelination begins after birth when oligodendrocytes (central nervous 
system), or Schwann cells (peripheral nervous system), wrap axons. Myelination of axons 
is crucial for proper propagation of nerve impulses; it is analogous to the wrapping of 
electrical wires allowing for more efficient and further transmission of electricity. The 
5 
 
maximum rate of myelination in rats occurs at twenty days after birth, where myelin is 
created at the rate of 3.5 mg per day, and at this time only roughly 15% of adult levels of 
myelin has accumulated 24. MAG expression begins very early in the process of 
myelination and is believed to play a role in the initial interactions of the membranes of 
oligodendrocytes/Schwann cells that helps to wrap axons. MAG expression remains high 
in adults, which reflects its role in axon-myelin maintenance 25. Studies of MAG null 
mice reveal MAG’s role in both initiation of myelination and maintenance, this 
phenotype is more pronounced in the CNS than the PNS 26. This was not fully 
appreciated initially due to the late onset of these effects and variations due to the genetic 
background of animals.  
Trans interactions of gangliosides GT1b and/or GD1a on nerve cells with MAG 
on oligodendrocytes/Schwann cells is important in cell-cell recognition. This interaction 
serves a dual purpose: it is necessary for the healthy maintenance of axons, but in injury 
states it is inhibitory, preventing axon regeneration. MAG is a lectin of the siglec family 
that binds the sialic acids on GD1a and GT1b, specifically the terminal sequence of 
NeuAc α2,3 Gal β1-3 GalNAc 13. When nerve cells are grown in vitro on a MAG coated 
substrate, their axon outgrowth is significantly inhibited 12. When sialidase is added to 
cell culture, the key terminal sialic acid is lost, converting GD1a and GT1b (MAG 
binding gangliosides) to GM1 (which does not bind MAG). In some types of nerve cells, 
sialidase allows for reversal of MAG mediated axon regeneration inhibition. Mice 
genetically engineered to lack these MAG binding gangliosides do not show inhibition on 
MAG coated surfaces, and they also have a similar phenotype to MAG knock-out 
animals 12,27. MAG-ganglioside interactions are also known to play a role in inhibiting 
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axon regrowth after spinal cord injury in vivo 28. Addition of sialidase in rat spinal cord 
injury models has been shown to improve both motor function and behavior. 
Combination of sialidase with chondroitinase ABC (ChABC), was not shown to improve 
recovery more so than sialidase alone29. ChABC cleaves chondroitin sulfate 
proteoglycans (CSPGs), another axon regeneration inhibitor present in the glia scar of a 
spinal cord injury 29. The signaling pathway for MAG mediated inhibition is known to 
require RhoA activation, but the signal transuding molecules leading from MAG-
ganglioside engagement to RhoA activation are not yet well established.  
 
Section 1.4 – Cis interactions – Lipid Rafts, Membrane Proteins and Ganglioside 
Interactions 
The plasma membrane separates extracellular and intracellular components, and 
molecules within the membrane are known to be organized in such a way to relay 
information between these segregated areas.  The bilayer is a stable structure, but it does 
allow for some transmembrane mobility of molecules and for them to readily diffuse 
laterally within the membrane 3. There are several states of the lipid bilayer that depend 
on both the temperature and lipids present. Lipid bilayers at physiological temperature 
often exist in the lipid-disordered (ld) phase which is characterized by high fluidity of the 
lipid acyl chains leading to high mobility of lipids within the membrane 3. When the 
temperature is lowered, the lipid acyl chains straighten and become ordered, so their 
movement laterally is limited, this is referred to the liquid-ordered (lo) phase 3. 
Glycosphingolipids have a tendency to form laterally separated liquid-ordered phases 
leading to glycolipid enriched areas that can influence the lateral movement of other 
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molecules within the membrane. The existence of lipid rafts is generally accepted, and 
these rafts are often thought of as signaling platforms that organize molecules within the 
membrane. Gangliosides are known to alter both the lipid composition and functionality 
of proteins within the membrane and lipid rafts 30-32.  Generally, 30-40% of the total lipid 
components of lipid rafts are sphingolipids and cholesterol, the remainder is generally 
made up of glycerophospholipids 33. Ganglioside GM1 is a commonly used marker of 
lipid rafts, and it known to co-localize in raft fractions with various membrane signaling 
proteins, including GPI-linked proteins and lipid-linked signaling molecules such as 
(among many others) Src family kinases on the inner membrane leaflet and the glutamate 
receptor families NMDAR 34 and AMPAR 35 on the outer membrane leaflet.  
In the mammalian brain, gangliosides are highly abundant membrane 
components. Their concentration is ten times higher than in many non-neuronal tissues 36. 
Ganglioside interactions laterally (cis) with proteins within the same membrane is known 
to play a role in both regulation and recognition pathways involved in cellular signaling 
and physiology 13.  The cis interactions of gangliosides with receptor tyrosine kinases is 
well documented, and one notable example is GM3 interacting with the insulin receptor 
(IR). Lateral interaction of GM3 with IR alters its sensitivity to insulin by inhibiting its 
tyrosine kinase activity 37. When GM3 levels are increased pharmacologically or 
genetically, insulin-stimulated phosphorylation of IR is suppressed and this leads to 
insulin resistance, which is a common indicator of type 2 diabetes. The insulin resistant 
phenotype can be rescued by reducing GM3 levels, thus manipulation of GM3 can be 
utilized to create a model system to study diabetes. The interaction of GM3 and IR 
involves movement laterally in the membrane to different lipid rafts. There is a 
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competition between caveolin-1 and GM3 to interact with IR, and it is this balance that 
can be altered in diabetes. When IR and caveolin-1 interact, the receptor is insulin 
sensitive, and when GM3 and IR interact, the receptor is insulin insensitive. The role of 
gangliosides in insulin resistance is now being investigated as a drugable target in 
diabetes, and glucosylceramide synthase inhibitors have been shown to be therapeutic in 
animal models38.  
 
Section 1.5 – Ganglioside biosynthesis and catabolic disorders in humans 
Gangliosides are abundant cell surface determinants on all vertebrate nerve cells, 
but their functions are largely unknown. Human disorders of ganglioside biosynthesis and 
catabolism currently have no cure. These are rare human disorders with a poor prognosis, 
where the patient suffers severe neurological deficits and often a shortened lifespan. A 
better understanding of the ganglioside metabolism and identifying the molecules that 
interact with gangliosides at the cellular level could lead to novel treatments. 
Human diseases of ganglioside catabolism have been characterized as lysosomal 
storage disorders. Defects in glycolipid degradation are known to cause various rare 
genetic diseases where the glycolipid accumulates in the lysosome 39,40. Since the 
turnover of glycolipids is highest in neural tissues, these diseases often have severe 
neurological impacts. These diseases are generally the result of defective glycosidases, 
and are known as glycosphingolipid storage diseases. One example Sandhoff disease (a 
GM2 gangliosidosis disease) is caused by mutations in a hexosaminidase subunit and 
results in the buildup of GM2, which eventually leads to nervous system failure. Figure 
1.2 shows the names of these metabolic disease and the names of enzyme(s) involved. 
The severity of these diseases depends on the level of enzyme impairment and these 
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neurologically affected enzymes generally have no available therapeutics 40. Not all cells 
are affected equally in these diseases since ganglioside metabolism can be highly variable 
between cell types and even between the same types of cells 41.  A better understanding 
of ganglioside metabolism at the single cell level could be used to generate novel 
therapeutics.  
 
Figure 1.2: Glycolipid storage diseases. Various diseases of sphingolipid 
catabolism are listed here, listing both the involved mutated protein (blue) and the disease 





With the advances in genome-wide linkage mapping and exome sequencing, rare 
ganglioside biosynthesis diseases have also been recently described. In these diseases, 
defective glycosyltransferases cause the complete absence of certain gangliosides (Figure 
1.3). Since the same total level of gangliosides is maintained, the ratios of simpler 
gangliosides are increased behind the block. Glycosidases function normally in these 
patients and no defects are seen in the breakdown of gangliosides in the lysosome. Two 
glycosyltransferases have been identified in rare human neurological diseases, GM3 
synthase (ST3GAL5, lactosylceramide α-2,3-sialyltransferase) and GM2/GD2 synthase 
(B4GALNT1, β-1,4-N-acetylgalactosaminyltransferase 1). Both of these diseases 
completely lack the four major brain gangliosides (GM1, GD1a, GD1b, GT1b). GM3 
synthase diseases lack GM3 and all of its biosynthetic derivatives, with an increase in 
lactosylceramide (LacCer) and (based on animal models) the O-series gangliosides GA2, 
GA1, GM1b, GD1α42. GM2/GD2 synthase diseases lack GD2 and GM2, including all of 
their biosynthetic derivatives (including the major brain gangliosides), with an increase in 
gangliosides GM3 and GD343. The severity of these diseases depends on the level of 
enzyme impairment; the described human diseases are often severe with null or nonsense 
mutations. Mutations in GM3 synthase cause severe infantile-onset epilepsy, 
developmental stagnation, blindness and death by the age of four42. Mutations in 
GM2/GD2 synthase cause variable early-onset spastic paraplegia and peripheral 
neuropathy, with neurological defects and sensitivity to seizures. The disease progression 
is highly variable with the mean of 32.2 +/- 19 years from onset to full peripheral 
paralysis and prognosis mortality is less severe than GM3 synthase diseases43. It is not 
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yet known why there is a difference in the severity of these two diseases; both lack the 
major brain gangliosides, but the outcome varies between them immensely. It is not 
known yet which contributes more to these diseases: the absence of complex gangliosides 
or the buildup of simpler gangliosides, or both. A fuller understanding of ganglioside 
interacting molecules could reveal which signaling pathways are impacted in these 
complex diseases.  
 
 
Figure 1.3: Glycolipid biosynthesis diseases. Defects in glycosyltransferases 
have been identified in rare human neurological diseases. Absence of GM3 synthase 
(ST3GAL5) or GM2/GD2 synthase (B4GALNT1) causes loss of the major brain 
gangliosides (GM1, GD1a, GD1b, GT1b) and other synthetic derivatives, coinciding with 





Chapter 2: Novel Ganglioside-Interacting Proteins  
 
Section 2.1 Introduction 
 
Protein-protein interactions are often well studied, but protein-ganglioside 
interactions are not yet as thoroughly examined. Techniques to study gangliosides are not 
well-known outside of the field, and the tools to study glycolipids lag behind other 
technologies because of their highly complex structures and properties.  Recently, there 
has been a large effort to make glycosciences accessible to the entire scientific 
community. The Nations Research Council of the National Academies recent roadmap 
report highlighted the field, and the committee recommended glycobiology as a high 
priority for future funding as its development has the possibility to impact multiple 
research disciplines 44,45. More investigators are beginning to study glycolipids since they 
are known to play roles in diverse signaling pathways involved in the immune system, 
insulin resistance, cancer, and development and stability of axons 1-3.  
The goal of this research project was to identify specific protein-ganglioside 
interactions and to study their functional significance. To enhance identification of 
structurally specific interactions, experiments were designed to detect differential nerve 
cell protein binding to two structurally distinct major brain gangliosides, GM1 and GT1b. 
As this project developed over time, nerve cell proteins used to study ganglioside 
interactions were first partially purified to enrich for membrane proteins, then membrane 
proteins at the cell surface. Although specific interactions of gangliosides with 
intracellular proteins are not discounted –it has been shown gangliosides are also 
expressed on the nuclear envelope and endoplasmic reticulum46– the focus of the current 
study was on interactions at the cell surface. The first experiments utilized a “medium” 
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stringency detergent, Brij-98, and a total membrane (all cellular membranes) protein 
sample. This was the least stringent method and relied on density centrifugation to isolate 
membranes in the presence of Brij-98 detergent (unpublished data, experiment 21, 2010); 
many non-plasma membrane proteins were isolated. In order to target the plasma 
membrane over total cellular membranes, we moved from relying on centrifugation 
methods to labeling and isolating cell surface proteins. The second iteration of this 
experiment utilized Brji-98 but paired it with a cell surface labeling method.  Using a 
non-cell permeable and cleavable (disulfide-containing) protein biotinylation reagent, the 
extracellular lysine residues on membrane proteins were preferentially labeled before cell 
lysis. Once cell surface proteins were labeled, cells were lysed and biotin-tagged proteins 
collected on an avadin column. Cell surface proteins were specifically eluted using DTT 
since this biotin was cleavable. This surface protein-enriched fraction was then incubated 
with GT1b- or GM1-derivitized beads. This method did prove to be more stringent than 
the previous method, but due to the stringency of the detergent we believe some non-
specific interactions occurred during lysis and obscured ‘authentic’ binders (unpublished 
data, experiments 26-29, 2010). The final iteration of this project involved utilizing both 
the cell surface labeling and Triton X-100, which is a more stringent detergent. We 
believe this method, paired with rigorous statistical analysis, has provided us with a 
protein complex that selectively interacts with GT1b- or GM1-derivitized beads 
(unpublished data, experiments 1-4, 2011). Statistical analyses revealed six GT1b-
selective binding proteins, three of which suggested that GT1b participates in the 
regulation of glutamate-receptor surface expression. These findings reveal a unique 
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functional and physical protein-ganglioside interaction; gangliosides have not previously 
been directly linked to glutamate receptor recycling at the plasma membrane.  
 
Section 2.2 Experimental Procedure 
Cerebellar Granule Isolation and Preparation -- All experiments utilized cerebellar 
granule neurons (CGNs) from newborn rats. CGNs were isolated in large numbers (yield 
~30 million cells per 4 animals) and represented a well-documented homogenous 
population of neuronal cells 33,47,48. Successful protocols for cell isolation and cell culture 
were adapted from Mehta et al. 12. CGNs were isolated from 5-6 day old rat pups. 
Cerebella were collected, and then dissociated using a papain dissociation kit 
(Worthington) following the supplier’s protocol. Briefly, isolated cerebella were 
incubated in a solution of papain and DNase for 30 min at 37°C, cells were triturated with 
a fire-polished pipette a total of two times at 15 min intervals. Cells were collected by 
centrifugation and re-suspended in NS21-containing medium (Neurobasal Medium 
containing 25mM KCL, 2mM Glutamine, 100 units/mL penicillin, 100ug/mL 
streptomycin, 1:50 NS21) at 1 million cells per mL and plated 2mL per 35mm poly-d-
lysine coated dishes 49. Cells were cultured at 37°C and 5% CO2 atmosphere for 12 days 
with half medium changes twice per week. 
Ganglioside-aldehyde beads – Gangliosides GT1b and GM1 were covalently bound to 
Dynabeads M-270 Amine beads (Invitrogen 14307D) after an ozonolysis reaction as 
described in Schnaar et al. 50. Briefly, gangliosides were oxidized at the 4-5 carbon 
double bond in the sphingosine using ozone. This reaction resulted in an aldehyde-
ganglioside derivative. The ganglioside-aldehyde was then linked to the beads via 
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reductive amination, covalently binding the ganglioside to the bead. Ozonolysis was 
improved through use of DMS to efficiently transform the gangliosides into the aldehyde 
derivative. Aldehyde-ganglioside structures were confirmed by TLC and MALDI-TOF 
before binding to Dynabeads.  
Triton X-100 method: surface membrane proteins –To enrich surface membrane proteins, 
living 12 day old in vitro neurons were incubated with a non-cell permeable and 
cleavable biotinylation reagent using the Pierce Cell Surface Protein Isolation Kit 
#89881(EZ-Link® Sulfo-NHS-SS-Biotin) before collection for cell lysis. Neurons were 
labeled according to manufacturer’s protocol using Sulfo-NHS-SS-Biotin for 30 min at 
4C. During this incubation, cells were either incubated or not, with a final concentration 
of 1 mM of non-cleavable ATPγS (Calbiochem 119120) with 3 mM MgCl2. If cells were 
treated with non-cleavable ATP this was included in all subsequent steps. This reaction 
was quenched and cells were scraped off plates, a slow spin was performed to remove 
nuclei (500 x g, 3 min), and the supernatant was collected and subjected to centrifugation 
at 4000 x g for 5 min at 4ºC.  The pellet was resuspended in 1 mL of detergent free buffer 
(20 mM HEPES, 150 mM NaCl; pH=7.2, 1:100 Protease inhibitor P8340 SIGMA), 
homogenized using a Potter-Elvehjem homogenizer (10 strokes on ice) and after an 800 x 
g 5-min spin, the supernatant was collected. The supernatant was spun at 100,000 x g for 
1 h at 4ºC. The pellet was solubilized in 0.5 mL 1% Triton X-100 buffer for 1 h at 4ºC 
with tumbling.  After 1 h the sample was centrifuged at 20,000 x g for 20 min at 4ºC and 
the supernatant was collected. Boitin-labeled (surface membrane enriched proteins) were 
isolated by incubating the soluble fraction with an avidin column and the bound proteins 
were eluted via DTT cleavage of the biotin. The enriched surface membrane proteins 
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were then incubated with GT1b or GM1 conjugated Dynabeads overnight with tumbling 
at 4ºC. After allowing sufficient incubation time, several washes were performed and 
bound proteins were eluted using NuPAGE® MOPS SDS Buffer kit (#NP0050, 
Invitrogen). The proteins eluted from ganglioside beads were either used directly for 
SDS-PAGE with subsequent Western blotting or were cleaned up via TCA-acetone 
precipitation for iTRAQ. 
TCA/Acetone protein precipitation for iTRAQ – The protein purification protocol was 
supplied by the Johns Hopkins University School of Medicine (JHUSOM) Mass 
Spectrometry and Proteomics. Briefly, after the protein sample was collected according 
to the NuPAGE® MOPS SDS Buffer kit (heating ganglioside-aldehyde protein bound 
beads at 70ºC for 10 min in the presence of DTT and LDS) a portion (2/3 total volume) 
was cleaned up for iTRAQ. An eight-fold volumetric excess of 10% TCA/90% acetone at 
-20ºC was added to the sample on ice and then vortexed, and incubated at -20ºC for 2-4 
h. The pellet was collected by centrifugation at 14,000 x g for 10 min at 4ºC and washed 
with the same volume of acetone (-20ºC) on ice and vortexed and then incubated at -20ºC 
for 10 min. The pellet was centrifuged at 14,000 x g for 10 min at 4ºC and the 
supernatant was removed. The pellet was allowed to briefly dry at room temperature then 
stored at -80ºC for subsequent iTRAQ analysis. 
Mass spectrometry, iTRAQ -- All mass spectrometry experiments were performed by the 
Johns Hopkins University School of Medicine (JHUSOM) Mass Spectrometry and 
Proteomics Facility. Samples were digested with trypsin and labeled using 8-plex iTRAQ 
kit according to the manufactures protocol (AB SCIEX). Samples were subjected to 
reduction (TCEP) and alkylation (MMTS) and subsequently proteolyzed with trypsin 
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(Promega) as previously described by Shevchenko et al. 51. Labeled peptides were 
combined and fractionated with strong cation exchange chromatography using a 
polysulfoethylA SCX column. Digested peptides were cleaned up using Oasis reverse 
phase clean up and then dried via SpeedVac.  Dried peptides were resuspended in 0.1% 
formic acid and loaded on a 75 µm x 2.5 cm trap packed with Magic AQ C18, 5 µm 
100 Å material (Microm Bioresources), then fractionated by reverse phase HPLC using 
an acetonitrile gradient. The instruments utilized were an LTQ-Orbitrap Velos MS 
(Thermo Fisher Scientific) interfaced with a 2D nanoLC system (Eksigent).  Peptide 
sequences were identified from the Rat Refseq database by using Mascot 
(www.matrixscience.com) software and further analyzed using Thermo Proteome 
Discoverer Program (Thermo Fisher Scientific, Inc.). A 1% False Discovery Rate 
threshold (FDR) was used for identification.  
Satistical Analysis of iTRAQ data, Bonferroni correction – 446 proteins identified from 
iTRAQ were further analyzed by applying the Bonferroni correction by Dr. Ingo 
Ruczinski of Johns Hopkins School of Public Health. This statistical method is one of the 
simplest and conservative methods to control error due to multiple comparisons. This 
method is more stringent than only using 1% FDR, and thus increased the chances of 
identifying authentic ganglioside-specific interacting proteins. Whereas about half of the 
identified proteins were differentially expressed according to the FDR (q-values), only 39 
proteins were differentially expressed between GM1 and GT1b protein binding according 
to Bonferroni (P<0.05/446=0.00011, see Section 2.3 Results).   
Western blot – ganglioside-interacting eluted proteins – Three biological replicates of 
12-day-old in vitro neurons were collected as described above in “Triton X-100 method: 
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surface membrane proteins.” Proteins were diluted in NuPage LDS buffer with reducing 
agents, loaded onto 4-12% Bis-Tris NuPage gels (Invitrogen). After gel separation, 
proteins were transferred to PVDF membranes utilizing the iBlot system (Invitrogen). 
Membranes were blocked with 5% nonfat dry milk in 0.1% Tween-20/1xPBS and 
subjected to Western Blot analysis using antibodies against Thorase (1:1000, Antibodies 
Inc.), GluR2 (1:1000, Antibodies Inc.), N-ethylmaleimide-sensitive fusion protein (NSF, 
1:2000, Abcam), glutamate receptor interacting protein (GRIP, 1:1000, BD Biosciences), 
and Nicalin (1:1000, Millipore). The blots were incubated overnight at 4C, then 
thoroughly washed and probed with horseradish peroxidase-conjugated secondary 
antibodies (Cell signaling) and visualized using an enhanced chemiluminescence kit (GE 
Healthcare). Images were collected on a Carestream Gel Logic imager and bands were 
quantified using ImageJ analysis software (NIH). ImageJ band densities of ganglioside-
interacting eluted proteins were normalized to the total density ‘pre-loading’ proteins that 
were not incubated with ganglioside beads prior to SDS-PAGE. 
Western blot - brain homogenates -- Three age and sexed matched mice were used per 
genotype for whole brain homogenate Western blotting. Mice were anesthetized with 
isoflurane and sacrificed; their brains were rapidly removed and homogenized in 
CellLytic MT mammalian tissue lysis reagent (Sigma). After centrifugation to remove 
non-soluble material, the soluble protein concentration was determined using a BCA 
assay (Thermo Scientific Pierce). Equal amounts (15 μg) of brain homogenate proteins 
were diluted in NuPage LDS buffer with reducing agents, and then were loaded onto 4-
12% Bis-Tris NuPage gels (Invitrogen). After electrophoretic separation, proteins were 
transferred to PVDF membranes utilizing the iBlot system (Invitrogen). Membranes were 
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blocked with 5% nonfat dry milk in 0.1% Tween-20/1xPBS and subjected to Western 
Blot analysis using antibodies against glyceraldehyde 3-phosphate dehydrogenase as 
control (GAPDH, 1:2000, Sigma), Thorase (1:1000, Antibodies Inc.), GluR2 (1:1000, 
Antibodies Inc.), N-ethylmaleimide-sensitive fusion protein (NSF, 1:2000, Abcam), 
glutamate receptor interacting protein (GRIP, 1:1000, BD Biosciences), Nicalin (1:1000, 
Millipore), and myelin associated glycoprotein (MAG, 1:500, kindly gifted by Dr. 
Norman, Cornell University, Ithaca, NY). The blots were incubated overnight at 4°C, 
then thoroughly washed and probed with horseradish peroxidase-conjugated secondary 
antibodies (Cell signaling) and visualized using an enhanced chemiluminescence kit (GE 
Healthcare). Bands were quantified using ImageJ analysis software (NIH).  Western Blot 
guidance, data on St3gal2/3 ganglioside-null mice, and additional brain homogenates 
were kindly provided by Dr. Seung-Wan Yoo (Johns Hopkins University).  
Animals – Two different genetic knockout mice models were utilized: St3gal2/St3gal3 
double nulls and B4galnt1-nulls. The mice were housed in a 12-h light/dark cycle with 
free access to food and water. All experimental procedures were approved by the Johns 
Hopkins Animal Care and Use Committee and were consistent with federal law and NIH 
regulations. Johns Hopkins Medical Institutions are accredited by the American 
Association for Accreditation of Laboratory Animal Care. The St3gal2 and St3gal3 
enzymes are responsible for GD1a and GT1b synthesis. St3gal2 enzyme is believed to be 
more strongly involved in glycolipid sialylation, while St3gal3 has a stronger influence 
on protein sialylation52. It is only when both St3gal2 and St3gal3 enzymes are removed 
(St3gal2/3 mice) that GT1b and GD1a are nearly completely knocked down and GM1 
and GD1b are increased to compensate52. The other mouse model utilized was the 
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B4galnt1 mice that lack the enzyme GM2/GD2 synthase (UDP-N-acetyl-D-
galactosamine:GM3/GD3 N-acetyl-D-galactosaminyltransferase, EC 2.4.1.92). They lack 
all the major brain gangliosides, GT1b, GD1a, GD1b and GM1, and instead have a 
buildup of the simpler gangliosides GM3 and GD3 53.   
Immunohistochemistry, Thorase staining of Ganglioside-null brains– Eight week old 
St3gal2 and/or St3gal3 wild type, single-, and double-null mice were intracardially 
perfused with PBS then 4% paraformaldehyde (PFA). Brains were dissected, post-fixed 
with 4% PFA, embedded in paraffin and sectioned to 5-μm thickness. Antigens were 
retrieved by boiling the sections in 10 mM sodium citrate (pH 6.0), this was followed by 
endogenous peroxidases inactivation with 3% hydrogen peroxide treatment. Sections 
were blocked in PBS with 10% serum, and then probed with antibodies for Thorase 
protein (1:200 Antibodies Inc.). The sections were then incubated with a biotin-
conjugated secondary antibody (1:250, Vector Laboratories), and then developed using 
the DAB-ABC kit (Vector) with nickel enhancer following the manufacture’s protocol.  
Slides were dehydrated and mounted using Kyrstalon mounting medium and imaged 
using a Nikon Eclipse 90 microscope and NIS image analysis software.  
Immunohistochemistry, Ganglioside staining of Thorase-null brains– Mice were 
anesthetized with isoflurane and transcardially perfused with PBS then 4% PFA. Brains 
were removed and postfixed in 4% PFA overnight at 4°C. After 24 h brains were 
cryoprotected in 20% sucrose, followed by 30% sucrose and frozen in isopentate at -70°C 
until use. Frozen tissues were embedded in M1 matrix compound and 20-μm slices (in 
situ slide stain) or 35 μm slices (free floating stain) were cut. Age, sex and histological 
brain level matched sections were stained in situ for gangliosides GT1b (anti GT1b-1, 
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Seigaku) and GM1 (anti GM1-1, Seigaku). Sections were blocked with serum/bovine 
serum albumin (BSA), and then stained with primary antibody overnight (1:2000). 
Sections were washed, then incubated with either Cy3-labeled secondary antibody (in situ 
slide staining, 1:200 Jackson Immunochemistry) or a biotin-conjugated secondary 
antibody (floating sections, 1:250, Vector). For the floating sections, the avadin-biotin 
complex was developed using the DAB-ABC kit (Vector) with nickel enhancer following 
the manufacture’s protocol. After development, floating sections were mounted and 
coverslipped on glass slides. In situ slides (Cy3) were also coverslipped after imaging 
using VectaSheild (Vector) and the edges were sealed with nail polish.  Data on floating 
stained sections was graciously generated by Dr. Marija Heffer (Osijek, Croatia).     
Cell surface GluR2 staining and imaging – Hippocampal neurons were collected from 
E18 rat pups as described in Makuch et al 54. Neurons were cultured for 16 d and some 
were treated with 20 mU/mL sialidase for the last 24 h before fixation. After 16 d in 
culture, neurons were fixed with 4%PFA/4% sucrose PBS solution, and then surface 
staining for GluR2 was performed. Coverslips were incubated with mouse anti-GluA2 
(15F1, a generous gift from Dr. Eric Gouaux, Oregon Health & Science University) at 
1:500 in a detergent free gelatin dilution buffer for 2 h at room temperature. Coverslips 
were washed, then cells were permeabilized with Triton X-100 containing gelatin dilution 
buffer and incubated with 1:250 anti-GluR2/3 rabbit antibody (JH4854, a generous gift 
from Dr. Richard Huganir, Johns Hopkins University). Coverslips were washed, and 
incubated with secondary antibodies (Alexa fluor 488 anti-rabbit (total) and Alexa flour 
546 anti-mouse (surface), Invitrogen) at 1:1000 in Triton X-100-containing gelatin 
dilution buffer for 1 h at room temperature. Coverslips were washed then mounted on 
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glass slides with Fluromount-G (Southern Biotech) and imaged using a Zeiss LSM 510 
Meta Confocal microscope utilizing a 63x oil objective. Hippocampal collection and 
staining was kindly provided by Olof Lagerlöf of Dr. Richard Hunagir’s laboratory 
(Johns Hopkins University).  
Statistical analyses – All quantified data utilized for statistical analyses are the result of at 
least three biological replicates. Error bars represent the mean +/- the standard error. 
Statistical analyses on two experimental conditions were performed using a 
homoscedastic (equal variance) method via Student-T-test. One Way Analysis of 
Variance (ANOVA) and pairwise multiple comparison procedures (Holm-Sidak method) 
were utilized when comparing three or more experimental conditions (SigmaPlot, Systat 
















Section 2.3 Results 
A reproducible method was established for ganglioside conjugation to amino 
beads for use in affinity chromatography. Subsequently, four biological replicates of 
cerebellar granule neurons in culture had their surface proteins biotin tagged, solubilized 
with detergent, enriched via biotin/avidin pull down before affinity chromatography of 
equivalent samples over GT1b- and GM1-derivatized beads. Rigorous Bonferroni 
statistical correction for multiple comparisons revealed differential interacting proteins to 
both GT1b- and GM1-derivertized beads reaching a p value of ≤0.0001. Subsequent 
experiments validated the selective binding of Nicalin, NSF, and Thorase to ganglioside 
GT1b and revealed selective binding of AMPA receptors to GM1. The data support a 
model in which gangliosides contribute to the steady state surface expression and subunit 





Table 2.1: GT1b-associated proteins 
The listed proteins bind selectively to GT1b, beating the Bonferroni statistical correction 
(p < 0.0001), which most conservatively accounts for multiple comparisons.  Of these, 
Thorase, NSF and Nicalin (red font) were chosen for further study based on their 
proposed common roles in regulating plasma membrane protein recycling/fusion. 
Gangliosides are known to be in membranes of vesicles as well as at the surface of 
cells55,56. Subsequent studies (below) indicate that NSF, Nicalin and Thorase are in a 
complex. Two of these proteins were confirmed to selectively interact with GT1b via 
Western blotting (NSF and Thorase). NSF and Thorase were shown to interact with each 
other via immunoprecipitation. Immunopreciptation of Nicalin resulted in pull-down of 









Table 2.2: GM1-associated proteins 
Thirty-three total proteins beat the Bonferroni correction (p < 0.0001) for specifically 
associating with GM1 (the 16 ribosomal proteins are not listed). Ganglioside GM1 is a 
low abundance ganglioside in cerebellar granular neurons. Reticulon-4 (Nogo) has been 
extensively studied as an important inhibitor of neuronal regeneration after injury, and 
could be an interesting candidate for future studies. These proteins were not studied 
further, but are included here as reference to demonstrate there are also proteins that 







Figure 2.1: Selective association of NSF, Thorase and GluR2 with gangliosides and 
its abrogation by ATPγS 
Biological triplicates are denoted by the three different colors. Differential binding is 
seen for these proteins between GM1 and GT1b. GluR2 specifically associates with GM1 
and this is ATP state dependent. In the presence of non-cleavable ATP (ATPγS) GluR2 
interaction is lessened. GluR2 does not associate with GT1b - this is the opposite of 
Thorase. GluR2 and Thorase are known to interact57. NSF is known to interact with 
Thorase and this plays a role in AMPAR recycling at the neuronal membrane (Ted and 






Figure 2.2: Quantification of selective ATP-regulated GluR2 binding to GM1 
Biological triplicates were probed for GluR2 binding and normalized to pre-loading 
controls. GluR2 shows specificity for ganglioside GM1, and this association is 
diminished in the presence of ATPγS. GM1 is known to co-localize in raft fractions with 
various membrane signaling proteins, such as the glutamate receptor families NMDAR 
34and AMPAR 35. While they have been shown to co-localize to the same lipid raft areas, 
glutamate receptors and gangliosides have never been formally linked in a signaling 
pathway. Statistical significance was determined via one-way ANOVA, p values less 










Figure 2.3: Quantification of selective ATP-regulated Thorase binding to GT1b. 
Biological triplicates were probed for Thorase binding and normalized to pre-loading 
controls. Thorase preferentially associates with GT1b, and this interaction is diminished 
in the presence of ATPγS. Statistical significance was determined via one-way ANOVA, 













Figure 2.4: Quantification of selective ATP-regulated NSF binding to GT1b 
Biological triplicates were probed for NSF binding and normalized to pre-loading 
controls. NSF preferentially associates with GT1b, and this interaction is diminished in 
the presence of ATPγS. Statistical significance was determined via one-way ANOVA, p 





Figure 2.5: Selective ganglioside binding by Thorase, NSF and GluR2 is diminished 
in the presence of ATPγS.  
A summary of Figures 2.2-2.4. Biological triplicates of cell surface ganglioside-
interacting proteins were Western blotted for NSF, Thorase and GluR2. A representative 
blot from the replicates is shown in (A). NSF and Thorase (B, C) statistically and 
preferentially associate with GT1b, while GluR2 associates with GM1 (D). These 
interactions are significantly diminished in the presence of non-cleavable ATP (ATPγS). 
Statistical significance was determined via one-way ANOVA, p values less than 0.05 are 




Figure 2.6: Expression of Thorase but not GRIP is increased in GT1b/GD1a 
deficient mouse brains. 
Mice with knockouts of various sialyltransferases were studied. The double nulls 
St3gal2/3 do not express GT1b (or GD1a), instead expressing an elevated level of GM1 
(and GD1b). The single knockouts express normal (St3gal3-null) or ~50% diminished 
(St3gal2-nulls) GT1b. Both enzymes need to be knocked out to prevent GT1b expression. 
Thorase expression is significantly increased in the double-null mice, while another 
player in the Thorase pathway, GRIP, is unaltered. All intensity values were normalized 
to GAPDH levels to account for protein loading variations. Experiment performed by Dr. 
Seung-Wan Yoo, Johns Hopkins University. Statistical significance was determined via 




Figure 2.7: Expression of Thorase, but not GluR2 or Nicalin is increased in 
B4galnt1-null (complex ganglioside deficient) mouse brains. 
Mouse brains from animals with a genetic knockout of the 
N-acetylgalactosaminyltransferase gene B4galnt1 were probed for Thorase, GluR2 and 
Nicalin expression. These animals lack the four major complex gangliosides (including 
GM1 and GT1b) and instead have a buildup of the simpler gangliosides GM3 and GD3. 
Thorase (B), but not GluR2 (C) and Nicalin (D), shows a significant increase in 
expression in null brains. The impact of the increase in Thorase expression of 
ganglioside-null animals is not yet known. Since the same relative level of increased 
Thorase expression is seen in two different ganglioside-null genetic models (St3gal2/3- 
and B4galNT1-nulls) there is likely a link between the steady state expression of 
ganglioside and that of Thorase. All intensity values were normalized to GAPDH levels 
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to account for protein loading variations. Brain homogenates kindly provided by Dr. 
Seung-Wan Yoo (Johns Hopkins University). Statistical analyses were performed using a 
homoscedastic (equal variance) method via Student-T-test, p values less than 0.05 are 













Figure 2.8: Thorase immunohistochemical staining in GT1b/GD1a knockout mouse 
brains.  
Mice with knockouts of the indicated sialyltransferases were immunohistochemically 
stained for Thorase to study spatial expression. Thorase is a heterogeneously expressed 
protein with relatively high expression in hippocampal CA1 pyramidal cells57. The 
St3gal3-nulls and wild type (WT) do show some Thorase staining in the hippocampus, 
but this appears to be elevated  in St3gal2-nulls and more so in St3gal2/3-double nulls. 
St3gal3-nulls defect is mainly in protein sialylation while St3gal2-nulls show more 
pronounced lipid sialylation defects52. Scale bar 0.2 mm. Brain sections were kindly 






Figure 2.9: Immunohistochemical staining of gangliosides in Thorase knockout 
mouse brains 
To investigate if there were differences in brain ganglioside distributions in Thorase-null 
mice, immunohistochemistry of the four major brain gangliosides, GM1, GD1a, GD1b 
and GT1b was performed. There were no gross changes in the localization of 
gangliosides in wild type and null brains, although intensity changes may be apparent 












Figure 2.10: Thin layer chromatography of gangliosides in Thorase-null mouse 
brains. 
To quantitatively establish if there are differences in brain gangliosides in Thorase-null 
animals thin layer chromatography (TLC) was performed. Wild type (W), null (K) and 
heterozygote (H) brain gangliosides were extracted from age matched mice. Gangliosides 
migrate in a well-defined manner during TLC and can be identified using standards as 
migration markers. Bands were identified and quantified using ImageJ software. Analysis 
revealed a statistically significant shift from a-series to b-series gangliosides in Thorase-
null mice. Mouse brain samples were kindly provided by Dr. George Umanah, Ted 
Dawson and Valina Dawson, Johns Hopkins University. Statistical analyses were 
performed between wild type and null animals using a homoscedastic (equal variance) 




Figure 2.11: Sialidase treated hippocampal neurons show temporal loss of GluR2 
subunits from the cell surface.  
Wild type rat hippocampal cells were cultured for 16 days in vitro, and then 20 mU/mL 
sialidase was added to the media and incubated for 24 or 48 h. Sialidase (also called 
neuraminidase) is a robust enzyme that cleaves sialic acid residues from both 
gangliosides and sialylated glycoproteins28. Temporal changes can be seen in glutamate 
receptor expression on the surface due to sialidase treatment. After 24 h, there is an 
increase in smaller puncta and less intense GluR2 surface staining. This indicates loss of 
AMPA receptors at the surface. This trend is reversed by 48 h, indicating there is some 
compensatory mechanism (e.g. homeostatic plasticity) to restore AMPA receptors to non-
treated levels despite the presence of sialidase at 48 h. Cell culture and staining was 
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Figure 2.12: Sialidase shows no loss of activity even 72 h after addition to cultures.   
To ensure the reversion of AMPA receptors from the 24 vs. 48 hour treatments seen in 
Figure 2.11 was not due to loss of enzyme activity, ganglioside immunohistochemistry 
and sialidase activity determinations using 4-methylumbelliferyl-alpha-D-N-
acetylneuraminate as substrate were preformed29. Cerebellar granular neurons were 
grown for 12 days in vitro then 20 mU/mL sialidase was added to the media for 24, 48 or 
72 h. At each time, media was collected for sialidase assays, and cells were fixed with 
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4% paraformaldehyde for ganglioside immunostaining. Cell density and health was 
similar between treated and non-treated cells as seen in Hoffman imaging. Sialidase 
treatment resulted in ganglioside conversion from GT1b to GM1, and this alteration was 
unchanged between 24 and 72 h. Sialidase activity in the medium was equivalent over the 
same time period. This suggests the changes seen in GluR2 surface expression in Figure 
2.11 between 24 and 48 h sialidase treatment is not due to a loss of sialidase activity over 













Figure 2.13 Model of ganglioside lipid raft segregation 
Gangliosides are known to alter both the lipid composition and functionality of proteins 
within the membrane and lipid rafts 2,30,32 Our data support a model of different flavors of 
ganglioside lipid rafts segregating proteins away from each other. NSF, Nicalin and 
Thorase interact with ganglioside GT1b, most likely through Nicalin. GluR2 interacts 
with GM1. In the absence of ATP, Nicalin, Thorase and NSF are separated from AMPA 
receptors. Since these molecules are separated, this allows GluR2-containing AMPA 
receptors to remain at the plasma membrane. When ATP is added to the system these 
proteins dissociate from their ganglioside lipid rafts and can diffuse to interact laterally 
within the membrane. This causes Thorase to bind to GluR2 and internalize the GluR2-
containing AMPA receptors. When GT1b is defective this disrupts the GT1b lipid rafts 
and leads to a decrease in surface AMPA receptors, as seen with treatment of nerve cells 
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with sialidase. Currently this model is speculative, and further research is needed to flesh 
























Section 2.4 Discussion 
Despite their abundance at the plasma membrane, ganglioside signaling pathways 
are not well understood. Many gangliosides localize to raft fractions, and due to ease of 
identification GM1 is known to co-localize in raft fractions with various membrane 
signaling proteins, such as the glutamate receptor families NMDAR 34and AMPAR 35.  
While they have been shown to co-localize to the same lipid raft areas, glutamate 
receptors and gangliosides have never been formally linked in a signaling pathway. Our 
recent work suggests that gangliosides may have a direct link to regulating glutamate 
receptor recycling from the neuronal membrane.  
Ganglioside interacting proteins at the plasma membrane 
Gangliosides are known to interact with a variety of proteins at the plasma 
membrane both in cis and trans as described in sections 1.3 and 1.4 in the Introduction. 
These interactions can occur between the ganglioside and protein directly, or via 
ganglioside and N-glycan interactions. Despite the interaction mechanism, these 
interactions rely on the glycan moiety of the ganglioside. We discovered novel 
ganglioside specific interacting proteins that implicate gangliosides as regulators of 
neuronal excitability, and that could explain why human ganglioside metabolic diseases 
are associated with seizures.  
AMPA receptor recycling, the role of NSF and Thorase 
Synaptic plasticity is a crucial process in learning and memory, regulation of 
AMPA receptors (AMPARs, also referred to as Glutamate receptors or GluR/GluA) on 
the synaptic membrane plays a role in this process. AMPA receptors are the main 
ionotropic glutamate receptors that mediate fast excitatory synaptic transmission in the 
brain58. AMPA receptors are tetramers, made up of homologous subunits GluA1-4 (also 
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referred to as GluR1-4). These receptors are generally composed of two identical 
heterodimers; GluA1/2 is the most common in mature hippocampal pyramidal neurons 
followed by GluA2/358,59. GluA4 generally forms homodimeric receptors and they are the 
main AMPARs expressed during synaptogenesis60. The GluR subunits mainly differ in 
their C-terminal domain and this is often where intracellular proteins interact with them. 
These intracellular proteins are indispensable for maintaining the proper subunit 
composition, numbers, and cellular localizations of AMPA receptors, and defects can 
lead to seizures and a variety of mental diseases such as autism and schizophrenia61.  
Trafficking of AMPA receptors to and from the synaptic membrane is regulated 
by subunit-specific AMPA receptor interacting proteins that either help stabilize or 
remove AMPA receptors from the membrane. Stability is achieved with the glutamate 
receptor interacting protein (GRIP) which delivers and stabilizes GluA2 at the synapse 58. 
Other proteins drive synaptic removal of GluA2-containing AMPARs from the 
membrane, for example “protein interacting with C-kinase 1” (PICK1). Some proteins 
are known to alter the interactions of GluA2-GRIP or GluA2-PICK1 which also affects 
AMPA receptor localization. Thorase is a recently described AAA+ ATPase protein that 
is both highly and heterogeneously expressed in the brain57.  GluA2, GRIP, and Thorase 
form a complex in the presence of ATP where Thorase disrupts the GluA2-GRIP 
complex. This disruption causes a dissociation of the AMPAR complex, and leads to 
endocytosis and removal of AMPAR from the membrane57. A related AAA+ ATPase, 
NSF, also plays a similar role, binding to GluA2 and disassembling GluA2-PICK1. This 
disruption results in stability at the membrane or recycling of AMPA receptor into 
postsynaptic membranes from intracellular compartments 62. AMPA receptors are known 
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to be in lipid rafts, and when these rafts are disrupted AMPA receptor exocytosis and thus 
surface expression is greatly reduced63. Addition of AMPARs to the synapse membrane 
results in long-term potentiation (LTP), but removal from the membrane results in long-
term depression (LTD). It is the balance of these two states that shapes neuronal synapses 
in the brain leading to the complex behaviors of learning and memory 58.  
The wild card, Nicalin:  
Our mass spectrometry studies revealed that Nicalin specifically interacted with 
ganglioside GT1b. Nicalin is a member of the aminopeptidase/transferrin receptor (TfR) 
superfamily, and is distantly related to the γ-secretase component Nicastrin.  γ-Secretase 
is a protein complex that consists of four transmembrane proteins including Presenilin 1 
or 2, Nicastrin, PEN-2 and APH-1.  γ-Secretase is involved in the proteolytic processing 
of a wide variety of transmembrane proteins through cleavage within the membrane64. 
Nicalin is a type I transmembrane glycoprotein that forms a distinct high molecular 
weight complex from γ-secretase65. Components of this complex include at least two 
proteins: Nomo (Nodal modulator) and transmembrane protein 147 (TMEM147).  Nomo 
is a 130 kDa protein with no recognizable functional motifs or previously known 
functions66. TMEM147 is an uncharacterized 22 kDa protein with seven transmembrane 
domains and a topology similar to APH-167. The molecular mechanisms of this Nicalin-
complex are not well understood, and there maybe still other proteins in this complex as 
its isolation is extremely sensitive to detergent isolation.  
Significant sequence similarity between Nicalin and Nicastrin is confined to a 
region of 180 residues which corresponds to a previously described aminopeptidase 
domain65. Both Nicastrin and Nicalin lack the amino-acid conservation required for 
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predicted catalytically active aminopeptidases, instead they are believed to be important 
in the formation of their respective protein complexes65. Unassembled monomeric 
components of these complexes are unstable and rapidly degraded67. The activity of the 
Nicalin complex has only been tested for the cleavage of amyloid precursor protein 
(APP), a known substrate of the γ-secretase complex65. Nicalin did not show activity for 
APP cleavage, and it has not yet been tested for cleavage of other proteins (such as the 
glutamate receptor).  
γ-Secretase cleaves substrates within their transmembrane domains, so it is 
possible that the lipid bilayer could alter activity and processivity of this complex, but 
this is not yet well established. Gangliosides are known to alter γ-secretase activity in a 
detergent-free lipid vesicle system.  Addition of total ganglioside extract (a mixture of 
brain gangliosides including GT1b, GM1, GD1a, GD1b and others) to these vesicles 
results in increased activity and decreased processivity of γ-secretase causing an 
elevation of Aβ42/4068. Neither the ganglioside(s) in this mixture, nor the molecular 
mechanisms responsible for gangliosides altering γ-secretase are known. In addition to in 
vitro systems, in vivo genetic mouse models of Alzheimer's disease have also been 
examined for ganglioside affects. Mice lacking GD3 synthase (St8sia1, lack b- and c-
series gangliosides) when crossbred with double-transgenic (APP/PSEN1) mouse model 
of Alzheimer's disease demonstrate a reduced Aβ production and aggregation. These 
triple-null mice are indistinguishable from wild type mice, and show no evidence of 
Alzheimer's disease69. Both in vitro and in vivo models suggest that gangliosides could be 
a novel target for cognitive defects that affect Alzheimer’s patients.  Due to similarity of 
γ-secretase and the Nicalin-complex it is conceivable that the Nicalin-complex could also 
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be involved in cleaving proteins at synapses, such as AMPA receptors and this activity is 
altered by ganglioside GT1b as suggested by our work. 
The Nicalin-complex has been described to be located in the endoplasmic 
reticulum (ER) based upon several criteria. The first being that Nicalin and Nomo are 
high mannose N-glycosylated proteins as demonstrated by degycoslyation experiments 
with N-Glycosidase F (PNGase F) and Endoglycosidase H (Endo-H)66. These 
experiments were carried out using HEK293T cell lysates in the presence of 0.1% SDS. 
Since no difference was seen in the bands created by PNGaseF (which cleaves most N-
linked glycans) and EndoH (which cleaves only high mannose N-glycans), Nicalin and 
Nomo were described as high mannose proteins. This description would be appropriate if 
they were resident ER proteins as they do not have access to the enzymes that convert 
high mannose to complex N-glycans in the Golgi. The Nicalin complex was also 
localized to the ER through immunocytochemistry and density gradient centrifugation co-
localization with the resident ER-protein calnexin65,67. Calnexin is involved in the folding 
and assembly of nascent proteins in the ER and recently a small fraction has also been 
demonstrated to be present on the plasma membrane70. These experiments were carried 
out in non-neuronal cell lines where often the Nicalin-complex components were 
overexpressed, so localization in nerve cells may be different. γ-Secretase is also 
described as an ER-protein, but small amounts are known to localize to GluR1 subunit 
AMPA receptor containing synapses, so it is possible that small amounts of the Nicalin-
complex also localize to synapses. γ-Secretase operates on both sides of the synapse with 
metalloproteases and this complex is important in cleaving proteins implicated in synapse 
remodeling and maintenance, including EphRs, ephrins, and cadherins71. The activation 
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of synaptic NMDA receptors stimulates the cleavage of N-cadherin by a proteolytic 
complex composed of metalloproteases, but γ-secretase cleavage of N-cadherin is not 
affected by synapse activity71. Synaptic scaffolding proteins, such as glutamate receptor-
interacting protein/AMPA receptor-binding protein (GRIP/ABP) are also known to 
associate with MT5-MMP proteases which are involved in the ectodomain shedding of γ-
secretase substrates71. This suggests a possible complex between γ-secretase and AMPA 
interacting proteins.  
 Nicalin has been only previously studied in the context of zebrafish development, 
where the Nicalin-complex, through an unknown mechanism, was shown to antagonize 
Nodal/TGFß signaling during mesendodermal patterning65. Nicalin function in the adult 
mammalian brain is unknown, but in Caenorhabditis elegans (C. elegans), orthologs of 
the Nicalin-complex are involved in nicotinic acetylcholine receptor (nAChR) 
assembly72. nAChRs are homo- or heteropentameric ligand-gated ion channels involved 
in excitatory neurotransmission, similar to AMPA receptors, but they respond to different 
neurotransmitters (acetylcholine and glutamate, respectively). In C. elegans loss of the 
orthologs of Nicalin (nra-2) and Nomo (nra-4) caused defects in synaptic nAChR subunit 
composition and function; this was partially rescued by expression of human Nicalin72. 
The interpretations of the Nicalin-complex effect on the nAChR’s in the literature are 
limited by their focus only on its ER-localization. Our studies suggest that Nicalin at the 
plasma membrane forms a complex with Thorase. This could be part of the yet unknown 
mechanism of Thorase regulation of surface proteins, where the Nicalin-complex could 
cleave the surface proteins and drive their internalization. Further investigation of this γ-
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secretase-like complex could reveal the molecular mechanism and additional novel 
binding partners/substrates of Nicalin and Thorase.  
Gangliosides and glutamate  
Gangliosides have been described as being associated through unknown 
mechanisms with glutamate in various pathways.  Exogenous addition of ganglioside 
GT1b to cell culture medium stimulates release of glutamate from neuronal-like cells 
(neuroblastoma cells and dorsal root ganglia-derived F-11 cells). This was specific and 
significant for GT1b only, other major brain gangliosides, like GM1, had no effect on 
glutamate release73.  Gangliosides have also been linked to nociceptive responses 
mediated through glutamate-dependent pathways. St8sia1-knockout mice, which lack b- 
and c-series gangliosides (including GT1b) but not asialo- and a-series gangliosides, are 
grossly normal, but display both thermal and mechanical allodynia and reduced 
nociceptive behavior during formalin injections.  During nociceptive responses, 
glutamate accumulates in the extracellular spaces in subcutaneous tissue. GT1b injection 
into tissue caused accumulation of glutamate, but this was not seen with other 
gangliosides like GM1. The GT1b injection pain response involved glutamate receptor 
activation and additional treatment with glutamate receptor antagonists or sialidase 
significantly reduced nociception and hyperalgesia74.  This study suggested that GT1b 
mediated nociceptive responses were through a glutamate-dependent pathway. 
Gangliosides have also been linked to sensitivity to glutamate excitotoxicity. Cerebellar 
granule neurons from B4galnt1-null (GM2/GD2 synthase-null) mice that lack the major 
brain gangliosides are more prone to apoptosis induced by glutamate excitotoxicity and 
elevated KCl. These null cells can be rescued by addition of exogenous GM1 or a semi-
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synthetic derivative of GM1 (LIGA20)75.  Ganglioside involvement in glutamate 
pathways has a disjointed and unclear history, from being involved in glutamate release 
from synapses to being linked to glutamate excitotoxicity. Our research suggests that 
gangliosides interact with AMPA receptors, one of the major glutamate receptors.  
 
Seizure phenotypes 
Epilepsy is a complex disorder affecting as many as 60 million people worldwide 
with no cure76. It is characterized by spontaneous recurrent seizures due to improper 
regulation of excitatory synaptic molecules. Severe seizures occur in Thorase-, NSF-, and 
AMPA-receptor-null individuals57,77-79. Mutations in ganglioside biosynthesis, such as 
GM3 synthase, also cause severe epilepsy through an unknown mechanism42. Our 
research suggests a connected signaling pathway between gangliosides and these 
proteins, that when misregulated leads to seizures. A fuller understanding of how 
gangliosides are linked to these proteins could lead to novel therapeutics for seizures.  
 
Section 2.5 Summary and Future Directions 
Gangliosides are abundant cell surface determinants on all vertebrate nerve cells, 
but their functions are largely unknown. Rare human disorders of ganglioside 
biosynthesis (and corresponding mouse genetic models) link altered ganglioside 
expression to severe seizures and other neurological disorders. The molecular mechanism 
that connects ganglioside expression to seizures has not been established.  An unbiased 
proteomic screen for ganglioside interacting proteins revealed a potential link between 
the expression of brain gangliosides and cell surface glutamate (AMPA) excitatory 
neurotransmitter receptors. AMPA receptors are key mediators of seizures and are an 
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emerging target for antiepileptic drugs in humans. Our data support a ganglioside-AMPA 
receptor interaction pathway that may regulate excitatory neurotransmission and whose 
dysregulation may result in seizure disorders. 
Future studies should determine the molecular mechanism and demonstrate a 
definitive link between the Nicalin-complex, gangliosides and AMPA receptors. A 
suitable Nicalin antibody for Western blotting will need to be developed or purchased for 
future experiments. Immunoprecipitation experiments will be undertaken to determine 
the conditions in which AMPA receptors and Nicalin-complex directly interact. Soluble 
forms of Nicalin and AMPA receptors will be developed or purchased for assays. ELISA 
assays will utilize these soluble forms to determine their binding specificity to 
gangliosides. Cleavage assays will be performed to determine if the Nicalin-complex has 
protease activity against AMPA receptors and related glutamate-receptors.  The binding 
of Thorase to Nicalin and Thorase to NSF will be studied in further depth, focusing on 
protein modifications (such as nitrosylation) and their effect on AMPA receptor 
trafficking. AMPA receptor trafficking in various ganglioside-null mice could also be 
explored through electrophysiology, immunohistochemistry and other assays to assess 









Chapter 3: Ganglioside Metabolism in Single Primary Neurons. 
Section 3.1: Introduction 
Although the biosynthetic and catabolic pathways of gangliosides have been 
largely elucidated, there is further need for metabolic studies, especially on the single cell 
level. Diseases caused by incorrect metabolism of gangliosides are well established and 
animal models of some of these diseases have been reported, but not all cells are equally 
affected in these models. The ability to measure variations in ganglioside metabolism in 
single healthy and diseased cells could lead to better understanding of these disorders.  
This project was a collaborative effort, with three laboratories working to develop 
novel methods to study ganglioside metabolism in single cells and cellular lysates. 
Tetramethylrhodamine (TMR) or boron dipyrromethene difluoride (BODIPY-FL) was 
conjugated to various gangliosides and glycosphingolipids by the Hindsgaul and Palcic 
labs at the Carlsberg Laboratories, Copenhagen, Denmark (Figure 3.0)80. These 
compounds allowed for very sensitive detection of the metabolic products down to the 
single cell level in the Dovichi lab (University of Washington, Seattle, WA and Notre 
Dame University, Notre Dame, IN) using capillary electrophoresis and laser fluorescence 
detection. This method has already been successfully used on various cell lines 81,82 and 
primary cultures 83,84.   
This project addressed several technological limits of single cellular metabolism 
utilizing metabolic cytometry. This technology allows for highly sensitive (yoctomole, 
10−24 mol, ~70 molecule range) analysis with an unprecedented dynamic range of nine 
orders of magnitude. This sensitivity allowed for the resolution of both small and large 
amounts of metabolites in the sub-picoliter volumes of the single cells. Great advances 
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were also made in multi-colored analysis of single cell metabolism through the addition 
of various BOIDPY/TMR compounds to cells and the creation of multi-colored analysis 
instruments.  Further refinement of this technology could answer many questions of 
metabolic processes on the single cellular level in various metabolic disease states 
ranging from cancer to lysosomal storage diseases.  
 
Figure 3.0 Examples of glycosphingolipid compounds tested. Over the lifetime of the 
metabolism project many compounds were tested, they fell into three generally 
categories: BODIPY, TMR or BODIPY-TMR conjugated. The sphingolipid core 




Section 3.2: Experimental Procedure 
Ganglioside compounds: 5-Carboxyl-tetramethylrhodamine (TMR) and boron 
dipyrromethene difluoride (BODIPY-FL) glycosphingolipids were created by the 
laboratories of Dr. Hindsgaul and Dr. Palcic utilizing the methods outlined in Larsson et 
al. 80. 
Dorsal Root Ganglion Isolation and Preparation – Dorsal root ganglion (DRG) neurons 
were isolated from 5-6 day old rat pups utilizing an established protocol with a few 
changes 12.  Collagenase concentration was increased to 10mg/mL and an additional 
purification step using a Percoll gradient was added to this protocol 83.  
Cerebellar Granule Isolation and Preparation -- Cerebellar Granule Neurons (CGNs) 
were isolated from 5-6 day old rat pups utilizing an established protocol 85. Cerebellum 
were collected, dissociated using the papain dissociation kit (Worthington) following the 
supplier’s protocol. Briefly, isolated cerebellum were incubated in a solution of papain 
and DNase for 30 min at 37°C, cells were triturated with a fire-polished pipetted a total of 
two times at 15 minute intervals. Cells were collected by centrifugation and re-suspended 
in NS21 containing medium (Neurobasal Medium containing 25mM KCL, 2mM 
Glutamine, 100 units/mL penicillin, 100ug/mL streptomycin, 1:50 NS21) at 1 million 
cells per mL and plated 2mL per 35mm poly-d-lysine coated dishes 49. Cells were 
cultured at 37°C and 5% CO2 atmosphere for various time points depending on the 
experiment being performed (7-12 days). For some experiments, cells were incubated 
with 10 µM cytosine- b-D-arabinofuranoside (AraC, Sigma-Aldrich, St. Louis, MO) 18 h 
after plating, and kept in the medium during growth to deplete the dividing non-neuronal 
cells. Medium changes were performed every two days.  
55 
 
Addition of fluorescent compounds -- was done in protein free medium (Neurobasal 
Medium containing 25mM KCL, 2mM Glutamine, 100 units/mL penicillin, 100ug/mL 
streptomycin – no NS21). Various carrier molecules (TMR, BODIPY, BODIPY-TMR) 
were tested over the lifetime of this project for efficient delivery of fluorescently labeled 
glycolipid (Chapter 3 Introduction Figure 3.0). For fatty acid free bovine serum albumin 
(BSA) carrier, equimolar amounts labeled glycolipid and BSA were pre-complexed in an 
ethanol-aqueous mixture (2:1) and then diluted to final concentration in protein-free 
growth medium. For MGP/MMP11/MMP14/Methyl-β-cyclodextrin carrier: a 1.5 
(carrier) to 1 (glycolipid) molar ratio was diluted to final concentration in protein-free 
growth medium. Cultures were washed, and incubated for various times with glycolipids 
(complexed with carriers) in protein-free medium, washed and cultured in protein-free 
medium and in some cases incubated for additional time before collection.  Incubation 
time, glycolipid and carrier molecule utilized and final concentration depended upon 
experimental conditions; please see figure legends for exact conditions.  
Single cell collection -- After incubation, cells were washed with 1xPBS and incubated 
with 2.5mg/mL trypsin and 0.9M EDTA (Invitrogen) for 15 min at 37°C to cause cells to 
lift off the plate. After 15 minutes, cells were removed from the plate via gentle pipetting 
and placed into a glass collection tube. An equal volume of 2.5mg/mL soybean trypsin 
inhibitor was added to quench the trypsin. The cells were collected via centrifugation (10 
minutes at 240g), and washed with 1xPBS. A portion of the live cells were counted and 
imaged on the Nikon TE200 microscope before fixation in 4% paraformaldehyde (PFA) 
for 12 minutes at room temperature. Fixed single cells were collected via centrifugation, 
washed with 10mM glycine/PBS, and stored in a glass Reacti-Vial (Thermo Scientific) in 
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10mM glycine/PBS. Cells were stored and shipped at 4°C to the Dovichi laboratory for 
capillary electrophoresis analysis against migration of known fluorescently labeled 
glycosphingolipids.  
Homogenate collection – Homogenate collection was carried out as single cell collection 
except cells were not fixed using PFA. After PBS washes, the supernatant was removed 
from the cell pellet and the pellet was suspended in a small volume (i.e. 100uL) of 
1%SDS in water and stored at -80°C until shipped on dry ice to the Dovichi laboratory 
for analysis.  
Capillary Electrophoresis – Capillary electrophoresis separation of labeled 
glycosphingolipids of single or homogenate cellular samples was carried out at the 
Dovichi laboratory according to established protocols 84.  The separation buffer and the 
capillary length were adapted over time and for single cell vs. homogenate 
measurements.  Generally, the separation buffer utilized was composed of 10 mM sodium 
tetraborate, 35 mM sodium deoxycholate, and 5 mM methyl-β-cyclodextrin. This allowed 
for resolution of peaks of known glycolipid standards as well as cellular samples well 
above the background noise. Single CGN cells were picked from non-neuronal cells 
based upon size and morphological differences in a microscope attached to the capillary 
electrophoresis machine.  Each cell was sandwiched between two plugs of a 0.4% Triton 
X-100 detergent solution which resulted in complete cell lysis and metabolite 
solubilization. Homogenates were loaded in a similar manner, minus the single cell 
injection. As the Dovichi laboratory developed this technology, two-color instruments 
were developed to allow for simultaneous analysis of dual labeled samples (such as TMR 
and BODIPY).  Two-color labeled single cells and homogenates were loaded into the 
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machine in a similar manner to one color labeled samples. Data was visualized using a 
























Section 3.3: Results  
 
Figure 3.1: Dorsal root ganglion (DRG) neurons cellular uptake of GM1-TMR. 
DRGs were collected from P5-6 rat pups, and after growing for 24 h growth in serum 
containing medium, cells were was washed with serum free medium. Cells were then 
incubated with 5µM GM1-TMR pre-complexed with equal molar BSA in serum free 
medium for 24 h before collection. DRGs were imaged at 20x using Nikon TE200 
microscope and images were collected via NIS Elements software. Differences in DRG 
cell size ranging from small to large cell bodies are evident in the Hoffman image and 




Figure 3.2: Homogenate DRG Electropherogram: A portion of DRGs treated with 
GM1-TMR from Figure 3.1 were collected as homogenates in 1% SDS as described in 
the method section. The largest peak is the substrate GM1, but this demonstrates these 
cells are capable of taking up our exogenously added compounds. Only catabolic (break-







Figure 3.3: Single cell DRG Electropherograms: 36 single DRGs were collected and 
fixed with 4% PFA as described in the methods section from DRGs in Figure 3.1. Each 
line is a single DRG neuron, and a large variation in uptake efficiency (peak height) and 
distribution can be seen from cell to cell. Some DRGs had almost flat traces, and others 




Figure 3.4: Labeling subsets of DRG neurons for analysis. DRGs were grown for 48 h 
and then fixed in 4% PFA and immunostained with IB4 (Griffonia  simplicifolia isolectin 
B4-FITC (Vector FL-1201 at 1:200)). IB4 selectively labels small non-peptidergic 
neurons which is one subset of DRG neurons 41. Large cells show no IB4 stain as 
expected (star) and various intensity of stain could be seen on other cell bodies. This 
could be a way to isolate a subpopulation of cells for injection by utilizing a biotin IB4 
coupled with NANOGOLD streptavidin and a LI silver enhancement kit (Molecular 
Probes/Nanoprobes Co). Ideally this would have allowed enrichment of homogenous 
cells from a heterogeneous population. In the end, this method did not result in dark 
enough staining to be seen by phase microscopy, and also resulted in massive cell loss 
during the handling steps (starting with ~150,000 cells after IB4/silver stain there were 
often less than 3,000 cells). Despite its short falls it could be an interesting future 





Figure 3.5: Homogenate CGN Electropherogram: Cerebellar granule neurons (CGNs) 
were grown for 10 days and then incubated with 5µM GM1-TMR pre-complexed with 
fatty acid free BSA for 24 h before collection for homogenate studies. Their homogenate 
electropherogram was similar to DRGs (Figure 3.2). Cerebellar granule neurons were 
chosen for all future studies because of their homogenous population (>90%), ease of 
isolation and uniform size (~10um). In addition, their ganglioside profile over many days 
in vitro is well established, and these cells express relatively high levels of the major 







Figure 3.6: CGN β-galactosidase inhibitor testing. Since only catabolic products are 
seen, Galactostatin, Phenylethyl ß-D-thiogalactopyranoside (PETG), and D-galactal 
which are all β-galactosidase inhibitors were tested. It was expected that they should 
prevent the complete breakdown of GM1-TMR to allow for it to sample anabolic 
pathways. CGNs were grown for 11 days in NS21 containing medium, and then washed 
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with NS21 free medium. Cells were then incubated for 1 h with an inhibitor (100mM D-
galactal, 0.25mM galactostatin bisulfate, or 4.15mM PETG), or NS21 free medium alone. 
After this hour cells were incubated for 19.5 h with 5µM TMR-GM1 which was pre-
complexed with equimolar fatty acid free BSA. Cells that were treated with inhibitor the 
hour before also had this inhibitor in the medium with the TMR-GM1. After 19.5 h 
incubation, cells were removed from the plate via trypsin and lysate homogenates were 
collected with 1% SDS.  Inhibitors decreased the ceramide-TMR peak along with 
increasing other catabolic peaks, but no anabolic products were seen with any inhibitor. 
D-galactal was the most promising inhibitor tested, with the largest reduction in the 
ceramide peak. All inhibitors were toxic at higher concentrations, so their concentration 
could not be increased further in an attempt to see anabolism. (Unpublished data 




Figure 3.7: Time course experiment with CGNs and sialidase inhibitor testing. Since 
only catabolic products have been seen previously with TMR, the sialidase inhibitor N-
Acetyl-2,3-dehydro-2-deoxyneuraminic acid (Neu5ac2ene Sigma, Aldrich D9050) and 
shorter incubation times with GM1-TMR were utilized to  try to improve anabolic 
product creation. CGNs were grown for 11 days in NS21 containing medium. They were 
washed with NS21 free medium and either incubated for 1 h with 2.5mM Neu5ac2ene in 
NS21 free medium, or in NS21 medium lacking Neu5ac2ene. After this hour cells were 
washed with NS21 free medium and then incubated for various times (3, 5, or 18 h) with 
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5µM GM1-TMR/BSA with or without 2.5mM Neu5ac2ene. Lysate homogenate were 
collected after these time points using trypsin to remove the cells from the plates and 
lysis via 1% SDS.  The inhibitor (black line) does increase the catabolic products and 
reduce the ceramide-TMR product, but no anabolic products are seen. Shorter incubation 
times lead to higher recovery of earlier catabolic peaks (GM1, GM2, GM3), as time goes 
on (18 h) all products in the absence of inhibitor shift heavily to ceramide-TMR. Shorter 
incubation time points may be best to study for better uptake of compounds. This 
inhibitor does not seem to increase anabolism and it cannot be increased without toxicity 







Figure 3.8: Neuronal and non-neuronal uptake of TMR-GM1. CGN cultures were 
grown in vitro for 7 days, with (B/D) or without (A/C) 10 μM cytosine-β-D-
arabinofuranoside (AraC, Sigma-Aldrich, St. Louis, MO) added 18 h after plating and 
kept in the medium thereafter to deplete dividing non-neuronal cells. Equimolar amounts 
of TMR-GM1 and fatty acid free BSA were pre-complexed and diluted to a final 
concentration of 5µM in NS21-free medium. CGNs were incubated with GM1-TMR for 
14 h and then collected via trypsin off the plate and either fixed in 4% PFA for 12 min at 
room temperature or lysed in 1% SDS. Hoffman images (A/B) demonstrate after 7 days 
in culture, CGNs have small refractile cell bodies that put out a mat of axons, with 
occasional flat non-neuronal cells as marked by an asterisk (*) which are more evident in 
the absence of AraC. After removing cells from the plate via trypsin, large non-neuronal 
68 
 
cells (>15µm) as seen in C, take up much more of the TMR compound compared to the 




















Figure 3.9: CGN homogenate alaysis. CGN cultures were grown in vitro for 7 days, 
with (A) or without (B) 10 μM cytosine-β-D-arabinofuranoside (AraC, Sigma-Aldrich, St. 
Louis, MO) added 18 h after plating and kept in the medium thereafter to deplete dividing 
non-neuronal cells. Equimolar amounts of TMR-GM1 and fatty acid free BSA were pre-
complexed and diluted to a final concentration of 5µM in NS21-free medium. CGNs 
were incubated with GM1-TMR for 14 h and then collected via trypsin off the plate and 
lysed in 1% SDS and stored at -80ºC until analysis. The CGNs treated with AraC had a 
metabolic profile that was less catabolic than the non-AraC treated samples which mainly 








Figure 3.10: Capillary electrophoresis of single cells. CGN cultures were grown in 
vitro for 7 days. Equimolar amounts of TMR-GM1 and fatty acid free BSA were pre-
complexed and diluted to a final concentration of 5µM in NS21-free medium. CGNs 
were incubated with GM1-TMR for 14 h and then collected via trypsin off the plate and 
fixed in 4% PFA for 12 min at room temperature. Cells were washed and collected in 
10mM glycine-PBS and stored in 4ºC until analysis. Cells were chosen for analysis based 
upon size and morphology. 31 neurons (A) have a very different metabolic profile from 
the 30 non-neuronal cells (B). Neurons demonstrate more catabolic products, where non-





Figure 3.11: Summary of single cell analysis data. This figure is a summary of values 
from the cells analyzed in the previous figure. Average total fluorescence (TMR) uptake 
was much higher in non-neuronal cells compared to neuronal cells (A).  The average 
intensity of the catabolic products for neurons vs. non-neuronal cells also showed marked 
differences in distribution (B). The dynamic range of the capillary electrophoresis 
machine allowed for quantification of TMR and its catabolites for each cell type.  The 
average of the single cell analysis from Figure 3.10 was reflective of the homogenate 





Figure 3.12: CGNs co-incubated with BODIPY-LacCer and TMR-GM1. CGN were 
grown for 7 days in vitro in NS21 containing medium. They were then washed with 
NS21 free medium, and Lac-Cer BODIPY and GM1-TMR was prepared by pre-
complexing with equal molar fatty acid free BSA and diluted to a final concentration of 
5µM of each compound. Cells were treated for 2 h with both compounds and then 
incubated for an additional 22 h in NS21 free medium to allow for incorporation of the 
BODIPY and TMR. Cells were imaged after 24 h total, cell bodies and axons were 
stained with BODIPY compound (green, A). Larger non-neuronal cells more readily took 





Figure 3.13: Two-color laser-induced fluorescence detection of CGN homogenate 
lysate co-incubated with LacCer-BODIPY and GM1-TMR. CGN were grown for 7 
days in vitro in NS21 containing medium. They were then washed with NS21 free 
medium, and LacCer BODIPY and GM1-TMR was prepared by pre-complexing with 
equal molar fatty acid free BSA and diluted to a final concentration of 5µM of each 
compound. Cells were treated for 2 h with both compounds and then incubated for an 
additional 22 h in NS21 free medium to allow for incorporation of the BODIPY and 
TMR labeled glycosphingolipids. Cells were collected off the plate via trypsin and after 
washing were lysed in 1% SDS.  GM1-TMR (green trace) showed only break down 
products, while the LacCer-BODIPY (blue trace) showed both anabolic and catabolic 





Figure 3.14: Single CGNs co-incubated with GM1-TMR and LacCer-BODIPY.  
CGN were grown for 7 days in vitro in NS21 containing medium. They were then 
washed with NS21 free medium, and LacCer BODIPY and GM1-TMR was prepared by 
pre-complexing with equal molar fatty acid free BSA and diluted to a final concentration 
of 5µM of each compound. Cells were treated for 2 h with both compounds and then 
incubated for an additional 22 h in NS21 free medium to allow for incorporation of the 
BODIPY and TMR. Cells were collected off the plate via trypsin and after washing were 
fixed with 4% PFA in PBS for 12 minutes at room temperature. Fixed cells were washed 
and stored in 10mM glycine-PBS at 4ºC until analysis. Seven cells were analyzed in the 
TMR or BODIPY channel (A) full channel, (B) expanded scale. Differences can be seen 
75 
 
in metabolism between the two compounds, TMR shows only break down products from 
the GM1-TMR added, with the highest peak being ceramide. BODIPY shows both 
anabolic and catabolic peaks, with the largest peak being the exogenously added LacCer. 
Peaks marked with “*” are artifacts, and peaks marked with “?” are unknown with no 

















Figure 3.15: The fluorescent tag utilized alters CGN uptake and distribution of 
exogenously added molecules. CGNs were grown for 12 days in vitro with NS21 
containing medium. After 12 days cells were washed with NS21 free medium and 
incubated for 2 h with 5µM TMR-GM1 (A) or 5µM BODIPY-GM1 (B) which were both 
pre-complexed with equal molar amounts of fatty acid free BSA. After 2 h incubation, 
cells were washed with NS21 free medium and incubated in NS21 free medium for an 
additional 22 h before collection. TMR-GM1 has bright staining of larger non-neuronal 
cells and is very punctate. BODIPY-GM1 stains the axons and smaller cell bodies of the 
CGNs in addition to some non-neuronal cells. This suggests that the fluorescent tag 
added to the same ganglioside GM1 core alters the uptake of these molecules. 




Figure 3.16: Electropherograms of CGNs treated with Lac-Cer-BODIPY and 
LacCer-TMR or treated with GM1-TMR and GM1–BODIPY. The importance of 
both glycosphingolipid core and fluorescence tag was explored to demonstrate the effects 
of these combinations on metabolic pathway sampling. CGNs were grown for 7 days in 
vitro in NS21 containing medium. Cells were washed with NS21 free medium and 
incubated for 30 minutes with a final concentration of 1.6uM glycosphingolipid pre-
complexed to an equimolar concentration of BSA then incubated for an additional 23.5 h 
in NS21 free media to allow incorporation before homogenate collection. Both TMR and 
BODIPY compounds were incubated at the same time in one sample: Cells were treated 
with the same glycosphingolipid core: one sample with TMR-LacCer (A) and BODIPY-
LacCer (C); the other with TMR-GM1 (B) and BODIPY-GM1 (D). Both the fluorescent 
tag (BODIPY (C/D) or TMR (A/B)) and also the starting glycosphingolipid (GM1 (B/D) 
or LacCer(A/C)) both make a difference in what metabolic pathways exogenously added 
molecules sample. BODIPY (green traces C/D) seems to be a superior molecule in terms 
of sampling both catabolic and anabolic pathways. TMR (red traces A/B) and GM1 
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(GM1-TMR B, GM1-BODIPY D) no matter what they are conjugated to only seem to 











Figure 3.17: CGNs treated with LacCer-BODIPY and various carriers. CGNs were 
grown for 7 days in vitro in NS21 containing medium. They were washed with NS21 free 
medium and incubated with 1.6µM LacCer BODIPY pre-complexed with either equal 
molar BSA or 1.5x molar 3-O-methyl-mannose polysaccharide MMP11. MMP11 is a 
mycobacterial glycan that is known to be a lipid molecule carrier. MMP11 was a 
generous gift of Dr. Todd Lowary from the Alberta Glycomics Centre, Edmonton, 
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Canada 87. Cells were incubated for 0.5 h with compounds then washed with NS21 free 
medium and incubated an additional 23.5 h in NS21 free medium before homogenate 
collection. A difference can be seen in fluorescent intensity, correlating to differences in 
uptake efficiently based upon the carrier utilized, with the classic carrier, BSA, being 
dimmer (A) and MMP11 (B) being much brighter when viewed at the same exposure, 
this is also reflected in the electropherogram (C).  Scale bar= 50 µm. (unpublished data 










Figure 3.18: CGN incubated with LacCer BODIPY or GM3 BODIPY-TMR and 
MMP11. CGNs were grown for 7 days in vitro in NS21 containing medium. They were 
washed with NS21 free medium and incubated for 30 minutes with 1.6µM GM3-
BODIPY-TMR or 1.6µM LacCer BODIPY final concentration; both were pre-complexed 
with 1.5x molar MMP11. After incubation cells were washed and incubated in NS21 free 
medium for an additional 23.5 h before single cell collection. Images A and B are taken 
at the same exposure, C is image B at a lower exposure time. Differences in fluorescent 
intensity, correlate to differences in uptake efficiently based upon the glycosphingolipid 
and fluorescent tag, with LacCer-BODIPY-FL-C5 being dimmer (A) than GM3-
BOIDPY-TMR (B) at the same exposure time. Scale bar = 50 µm (unpublished data 





Figure 3.19: CGNs treated with GM3-BODIPY-TMR and various carriers. CGNs 
were grown for 7 days in vitro in NS21 containing medium. They were washed with 
NS21 free medium and incubated with 1.6µM GM3-BODIPY-TMR pre-complexed with 
1.5x molar MMP11 or 1.5x molar methyl-β-cyclodextrin. Cells were incubated for 0.5 h 
with compounds then washed with NS21 free medium and incubated an additional 23.5 h 
in NS21 free medium before homogenate collection. Note the difference in intensity scale 
on the y axis. Methyl-β-cyclodextrin intensity was greater than MMP11, correlating to 
differences in uptake efficiently based upon the carrier utilized. Methyl-β-cyclodextrin 
was also brighter when imaged at the same exposure under fluorescence microscopy 





Section 3.4: Discussion 
What is metabolic cytometry? 
Metabolic cytometry is one way to study single cell metabolism. This method has 
been developed by Dr. Dovichi and it uses modern chemical instrumentation to monitor 
metabolism in single cells through exogenously added tagged molecules 88,89. 
Immunostaining experiments such as Figure 3.20 have revealed that the distribution of 
glycosphingolipids can be highly heterogeneous within neuronal populations 41. It has 
also been documented that not all cells are affected equally in glycosphingolipid 
metabolic diseases 40. These differences in cellular expression cannot be studied 
quantitatively by methods like immunohistochemistry, but rather need to be studied on 
the single cell level. Metabolic cytometry methods are desirable over these affinity 
reagent (like antibodies or toxins) methods, because these reagents can interfere with the 
normal cellular processes. Affinity reagents are also not practical for quantitation, as 
labeling each individual metabolite would lead to a resolution nightmare. Each metabolite 
would be seemingly impossible to tease apart with the limited available secondary 
antibodies and it would be hard to avoid spectral cross talk, ultimately limiting resolution 
and dynamic range.  
In order to view the metabolome in high resolution, we utilized metabolic 
cytometry. This method allows for all possible paths can be sampled given the pre-cursor 
added to cells samples that pathway, the dyes remain stable and the dyes can be separated 
using capillary electrophoresis (CE) and detected with high sensitivity laser-induced 
fluorescence. Detection limits are very fine, up to the yoctomole (10-24 mole, ~70 
molecules) level 84. Metabolic cytometry also allows for a large dynamic range to be 
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sampled, allowing for identification of both high and low abundance metabolites. 
Currently, our methods allow for an unprecedented dynamic range of nine orders of 
magnitude to be sampled 84. The fine detection limit and dynamic range allows for 
quantification at the molecular scale. This could lead to understanding of metabolism at 
the molecular scale, allowing for novel quantifiable differences to be seen between 




Figure 3.20: Rat DRGs triple-labeled demonstrate differential ganglioside 
localization. Sections were stained with anti-ganglioside mAb (green), neurofilament 
(red) and IB-4 (blue), co-localization of all three are shown in merged. This figure 
demonstrates the heterogeneity of ganglioside expression of neurons.  Scale = 20µm. 41.  
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Fluorescent compound, carrier, and glycosphingolipid combination is crucial to 
metabolic pathways sampled 
To visualize the metabolic pathways within a single cell exogenously added 
fluorescently tagged glycosphingolipids were added to cells. Since this was a tagged 
lipid, a carrier molecule had to be utilized to insure solubility and delivery. Both carrier, 
fluorescent tag, and glycosphingolipid used were altered over the lifetime of these 
experiments. The best combination so far that allowed for both maximum solubility, and 
sampling of catabolic and anabolic pathways, was a methyl-β-cyclodextrin carrier with a 
BODIPY tagged molecule with a GM3 glycosphingolipid core. 
Fluorescent tag – Historically, these studies began with 5-Carboxyl-
tetramethylrhodamine (TMR) compounds. TMR-GM1 and TMR-LacCer when 
complexed with BSA carrier, resulted in punctate staining in two different cultured nerve 
cell types (DRG/CGN) (Figure 3.1, Figure 3.15) which only demonstrated catabolism in 
electropherograms (Figure 3.2, Figure 3.5). TMR uptake was very high in non-neuronal 
cells both visually and by electropherograms, but also only showed catabolism (Figure 
3.8-3.11). We ruled out the punctate staining of TMR as being lysosomal as it did not 
localized to lysosomes as co-visualized with lysosomal marker LysoTracker green 
(Invitrogen L7526) (unpublished results experiment 16, 2011). Inhibitors of 
glycosphingolipid catabolism were utilized with TMR tagged glycosphingolipids in an 
attempt to prevent catabolism, to sample anabolic pathways. Both β-galactosidase 
inhibitors (Galactal, Galactostatin, Galactostatin Bisulfate, PETG) and sialidase inhibitor 
Neu5ac2ene did not result in sampling of anabolic pathways (Figure 3.6, Figure 3.7). 
While these inhibitors did increase some of the earlier catabolic peaks and shifted the 
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trend away from primarily all ceramide, they did not address the lack of anabolic 
pathways sampling. In the end, TMR as a carrier was not effective in sampling anabolic 
pathways even with catabolic inhibitors, so other dyes were explored. Boron 
dipyrromethene difluoride (BODIPY-FL) was the first alternative dye tested.  BODIPY 
compounds allowed for both anabolic and catabolic pathways to be sampled (Figure 3.13, 
Figure 3.14). Alterations to BODIPY changing its absorbance/emission spectrum allowed 
for even greater uptake by cells and we are able to utilized multiple BODIPY derivatives 
at the same time (i.e BODIPY-FL in green and BODIPY-TMR in red).  BODIPY-TMR 
which is a red emitting BOIDPY compound (Chapter 3 Introduction Figure 3.0) allowed 
sampling of both catabolic and anabolic pathways at an even greater intensity than 
BODIPY-FL (Figure 3.18). Currently, BODIPY derivatives are being explored for multi-
colored metabolic cytometry, and a three color system has already been created which 
could be utilized to study multiple channels of BODIPY derivatives simultaneously 
(personal communication Dr. Richard  Keithley). 
Glycosphingolipid – In addition to the fluorophore used, the core glycosphingolipid 
modified made a great difference what metabolic pathways were sampled. Over the 
course of these experiments, GM1, LacCer, and GM3 were the main glycosphingolipid 
cores studied. GM1-TMR and GM1-BODIPY-FL compounds only sampled catabolic 
products under the conditions tested, while LacCer-BODIPY-FL compounds sampled 
both catabolic and anabolic pathways (Figure 3.16). By adding a pre-cursor GM1 we may 
have limited ourselves to only sample catabolic metabolism. Since in the major 
ganglioside is GT1b in the CGNs tested, the exogenously added fluorescently tagged 
GM1 would have to be broken down into a pre-cursor like GM3 or LacCer to be able to 
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sample the beta ganglioside series which was dominant in these cells (see Figure 1.1 for 
the metabolic pathway). By studying LacCer, a precursor that can be made into either the 
alpha or beta gangliosides, we were able to sample both catabolic and anabolic products. 
LacCer uptake was more robust, and when paired with BIODIPY-FL we received the 
robust cellular uptake. The uptake was present in both neurites and neuronal cell bodies, 
as a strong, seemingly cell surface staining, with some non-neuronal cells taking up the 
dye as well. This was a stark contrast to the robust non-neuronal staining and mediocre 
punctuate staining of neurons by TMR compounds (Figure 3.15). Most recently, GM3 
derivatives were explored. GM3 is the glycosphingolipid at the branching point between 
the alpha and beta gangliosides and this core has shown even greater promise than 
LacCer-BODIPY-FL compounds. GM3-BODIPY-TMR compounds resulted in improved 
signal to noise and much brighter uptake as seen by fluorescence microscopy (Figure 
3.18).  
Carrier – The exogenously added tagged glycosphingolipid had to have a lipid carrier 
molecule to insure solubility and delivery to cells. Historically, equal molar amounts fatty 
acid free bovine serum albumin (BSA) and tagged glycosphingolipid was utilized. This 
ran into a solubility issue since the tagged glycosphingolipid was solubilized in ethanol, 
and BSA can precipitate in ethanol. Alternatives to BSA were explored that allowed for 
greater solubility and delivery. Known lipid carrying bacterial compounds were explored 
first 3-O-methyl polysaccharide (MMP11 and MMP14) and de-acylated methyl 
glucopolysaccharide (MGP) 90. MMP11 and MMP14 were a generous gift of Dr. Todd 
Lowary from the Alberta Glycomics Centre, Edmonton, Canada 87. MMP11, MMP14 and 
MGP delivered the tagged glycosphingolipid more efficiently than BSA, as seen both by 
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brighter fluorescence imaging of the cells and increased electropherogram intensity 
(Figure 3.17-3.18, unpublished data experiment 1, 2012). MMP11 was more effective 
than MGP and MMP14, but all of these molecules are intensive to synthesize, so we 
looked into the readily available alternative of methyl-β-cyclodextrin. When MMP11 was 
compared to methyl-β-cyclodextrin, delivery of GM3-BODIPY-TMR was more efficient 
with methyl-β-cyclodextrin as demonstrated both by higher intensity microscopy 
fluorescence and electropherograms (Figure 3.19, unpublished data experiment 4, 2012). 
Methyl-β-cyclodextrin will be used in future experiments for delivery, as this is far easier 
to obtain and cheaper than synthesizing MMP/MGP compounds.  
 
Section 3.5: Summary and Future Directions  
Ganglioside biosynthesis pathways are well established, but cell-to-cell variability 
in these pathways is not well known. Utilizing metabolic cytometry, ganglioside 
metabolism can be studied at the single cell level. Currently, this method is highly 
sensitive allowing for quantifiable differences to be seen with as few as 70 molecules. 
Better understanding ganglioside metabolism on the molecular level could shed light on 
genetic deficits in these pathways which have known nervous system pathologies in 
animal models and humans. Historically, these metabolic cytometry studies began as a 
simple rotation project on dorsal root ganglion (DRG) homogenates that have now 
blossomed into an extensive and fruitful collaborative effort. Our experiments 
demonstrated that primary neuronal cells can be harvested, successfully labeled with 
fluorescent ganglioside derivatives, and can be fixed and shipped across the county for 
analysis. Perhaps more importantly, our studies have demonstrated that our metabolic 
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cytometry methods can distinguish subpopulations of cells in mixed cultures (neurons vs. 
glia) which could be translated into in vivo work.  
Characterization of subsets of single cell types – Metabolic heterogeneity could be 
explored in cell types like DRGs, which are a known heterogeneous cell type. In our 
experiments, DRGs showed differences from cell to cell in uptake of the exogenously 
added fluorescent ganglioside derivatives 83. The most appropriate methods to distinguish 
homogenous subpopulations in this heterogeneous cell type would need to be fleshed out. 
We already know that our current methods can distinguish neuronal from non-neuronal 
cell types, and both of these cell types have different metabolic profiles (Figure 3.8-3.11). 
Also, we can cluster homogenous cell types metabolic electropherograms to see trends in 
subsets of cells in a heterogeneous population, but we would need an additional identifier 
in vitro to make this more meaningful 83.  We have tried affinity reagents in the past by 
attempting to label homogenous subsets of DRGs with IB4, but this did not produce 
robust results (Figure 3.4). Further development to characterize subsets of homogenous 
cells (i.e. diseased vs. healthy cells) within a larger heterogeneous population could lead 
to interesting metabolome discoveries that could translate our in vitro to in vivo 
discoveries.  
TMR vs. BODIPY – Over the course of this project two fluorophores were explored, 
BODIPY and TMR. BODIPY compounds often showed both catabolism and anabolism, 
while TMR compounds only showed catabolism. The differences we see in fluorescent 
tagged sampling of metabolic pathways are most likely due to their differences in 
structure. There is a difference in the charge, linker, and steric size of the fluorescent 
molecules utilized, and these all could affect the glycosphingolipid’s insertion into 
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membrane. Recently, Dr. Richard Keithley in Dr. Dovichi’s group found that the 
hydrophobicity of the dye plays a role in cellular uptake. Where order of most efficient 
uptake was: LacCer-BODIPY-FL, followed by LacCer-BODIPY-TMR, then LacCer-
BODIPY-650/665 (personal communication Dr. Richard Keithley). This suggests that the 
hydrophobicity of the dye could plays a role in membrane insertion, where the more 
hydrophobic dyes insert more readily into the membrane resulting in higher efficiency of 
uptake into cells. In addition to the hydrophobicity of the dye, the sterics of the molecule 
and linker could also play a role in membrane insertion efficiency. A recent paper on 
cholera toxin uptake via tagged GM1 into cells showed that the saturation of the acyl 
chain of GM1 was extremely important in retrograde trafficking from the plasma 
membrane. Unsaturated acyl chain GM1 sorted form the plasma membrane to the trans-
Golgi network and then to the endoplasmic reticulum, but if the acyl chain of GM1 was 
saturated it went to from the plasma membrane to endosomes 91. Perhaps, the longer 
linker with an extra carboxamide group and bulkier structure of the TMR compounds 
mimicked a saturation of the acyl chain, and lead to predominantly endosomal sorting. 
We only saw catabolic sampling of TMR compounds, and staining was punctuate, but it 
did not localize with LysoTracker green (Invitrogen L7526). LysoTracker is a pH 
dependent dye, and should not stain endosomes well, if at all. So, perhaps TMR 
compounds could localize to endosomes in our experiments. Studies with endosomal 
markers such as Invitrogen’s early or late endosomal markers (C10586 or C10588) which 
utilize GFP baculovirus expression vectors could co-localize with our punctuate TMR in 
vitro.  This could be a great tie in with the literature, and explain why we see punctate 
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TMR staining, but not lysosomal co-localization. In the future, both the hydrophobicity 
and sterics should be considered in the design of new fluorescent compounds.  
Continuing optimization of fluorophore, carrier, and glycosphingolipid core -- A large 
amount of effort went into optimizing the combination of fluorophore, carrier and 
glycosphingolipid to allow for efficient sampling of both catabolic and anabolic 
pathways. TMR compounds only demonstrated catabolism, while BODIPY compounds 
generally sampled both catabolic and anabolic pathways. We also found the 
glycosphingolipid core was essential in the pathways sampled, with GM1 only showing 
catabolic products, while LacCer and GM3 sampled both catabolic and anabolic 
pathways. The choice of carrier was also crucial for proper delivery of the tagged 
glycosphingolipid to cells; we found methyl-β-cyclodextrin to be a superior carrier to 
BSA. While various inhibitors of catabolism were tested, we ultimately found that the 
best way to sample both catabolic and anabolic pathways would be to alter fluorophore, 
carrier and glycosphingolipid choice. Currently, our favored combination is a BODIPY 
based tag on GM3 or LacCer and utilizing a methyl-β-cyclodextrin carrier. In the future 
new BODIPY derivatives, carriers and glycosphingolipid core combinations should be 
explored to maximize metabolome sampling.  
Multicolor analysis – We have tracked two different dyes (TMR and BODIPY-FL) 
simultaneously, but the ability to sample more color spectrums would allow for a larger 
portion of the metabolome to be sampled concurrently. Currently, the Dovichi laboratory 
is working on a three color system that can measure BODIPY-FL, BODIPY-TMR, and 
BODIPY-650/665 (personal communication Dr. Richard Keithley). These dyes have 
already been tested on differentiated PC12 cells, and extending this research into primary 
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CGNs or other primary cells should be undertaken. Utilizing multicolored analysis would 
allow for a wider picture of the metabolome, and could assist technically in accelerating 
fluorophore, carrier, and glycosphingolipid core combination optimizations. 
In vivo work- Ultimately our in vitro work could one day be translated into animal 
models of metabolic diseases. Utilizing single cell metabolic cytometry could reveal 
molecular differences in metabolism between diseased and healthy cell populations. Once 
we understand the disease on a single cell level, this could lead to novel targeted 
therapeutics these subsets of cells. We have begun work to bridge our in vitro work to in 
vivo. Tissue slice cultures offer the control of an in vitro environment, but supply tissue 
architecture that is more in vivo like than dissociated cultures.  Yellow fluorescent protein 
(YFP) expressing motor neurons allow us to see a subset of cells in the motor cortex slice 
culture. Incubating the motor cortex slice with GM3-BODIPY-TMR allowed us to 
visualize both green motor neurons and cells that had taken up GM3-BODIPY-TMR. 
This method could eventually allow us to translate our single cell work into animal 
models but it needs to be optimized. Currently, the GM3-BODIPY-TMR is taken up by 
seemingly every cell type, and results in an overwhelming red stain. The combination of 
the thickness of the slice culture and intensity of BODIPY-TMR makes it hard to 
distinguish tissue architecture. The technical aspect of preparing the slices for imaging 
and optimal concentration and incubation of fluorescent glycosphingolipid needs 
improvement.  Once the technical aspects of tissue preparations are optimized, there are 
many readily available animal models of metabolic diseases that could really show off 
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